Related Experiment Video
Updated: Mar 23, 2026

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
Prophylaxis of venous thromboembolism in cancer patients
Corinne Frere1,2, Ludovic Doucet3,4, Dominique Farge5,6
1a Assistance Publique Hôpitaux de Marseille, Timone Hospital, Service d'Hématologie biologique , Marseille , France.
Abstract:
Venous thromboembolism (VTE) is an independent prognostic factor and the second leading cause of death in cancer patients. VTE is however a largely preventable disease when thromboprophylaxis is appropriately used. As recommended worldwide by international Clinical Practice Guidelines, cancer patients undergoing surgery or hospitalization for acute medical illness or with reduced mobility should benefit from thromboprophylaxis, in the absence of bleeding or other contraindications to anticoagulants. Thromboprophylaxis in cancer outpatients receiving systemic therapies is still under debate, except for pancreatic ambulatory cancer patients where prophylaxis confers a sustained reduction in VTE. Numerous strategies are currently developed to improve VTE prophylaxis practices in cancer patients, and to elucidate the best appropriate anticoagulant regimen for each individual cancer patient.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism III: Nursing Management
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Peripheral Artery Disease V: Postoperative Nursing Management

